Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy (Retraction in: American Journal of Nephrology (2009) 30:6 (563))

American Journal of Nephrology

Volumn 24, Issue 5, 2004, Pages 543-548

  Nakao, Naoyuki ^a   Seno, Hachiro ^a   Kasuga, Hirotake ^a   Toriyama, Takanobu ^a   Kawahara, Hirohisa ^a   Fukagawa, Masafumi ^b  

^a Nagaya Kyoritsu Hospital   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood pressure monitoring, ambulatory; Chronic renal failure; Combination treatment, clinical trials; Combination treatment, losartan and trandolapril; Losartan; Office blood pressure; Renin angiotensin system blockade; Trandolapril

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; TRANDOLAPRIL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; FEMALE; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; KIDNEY DISEASES; LOSARTAN; MALE; OFFICE VISITS; TIME FACTORS;

EID: 10644260221     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081953     Document Type: Article

References (12)

1. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003;361:117-124.
2. Covic A, Goldsmith DJ: Ambulatory blood pressure monitoring in nephrology: Focus on BP variability. J Nephrol 1999;12:220-229.
3. Covic A, Goldsmith D: Ambulatory blood pressure monitoring: An essential tool for blood pressure assessment in uraemic patients. Nephrol Dial Transplant 2002;17:1737-1741.
4. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving HH: Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. Kidney Int 1996;50:579-585.
5. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-999.
6. Ferrari P, Marti HP, Pfister M, Frey F: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002;20:125-130.
7. Jacobsen P, Andersen S, Rossing K, Hansen B, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002;17:1019-1024.
8. Rossing K, Jensen BR, Christensen P, Parving HH: Dual Blockade of the renin-angiotensin system in diabetic nephropathy. Diabetic Care 2002;25:95-100.
9. Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004;43:260-268.
10. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
12. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG for the African-American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK Trial. JAMA 2002;288:2421-2431.